Scientific article

Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients

Published inArthritis and rheumatism, vol. 58, no. 2, p. 586-594
Publication date2008

OBJECTIVE: To assess the efficacy of systemic corticosteroids (CS) alone as first-line treatment in patients with Churg-Strauss syndrome (CSS) without poor-prognosis factors, as defined by the Five-Factors Score (FFS), and to compare the efficacy and safety of oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC) as adjuvant immunosuppressive therapy for treatment failure or relapse. METHODS: This multicenter, prospective, randomized, open-label therapeutic trial included 72 patients with newly diagnosed CSS (FFS of 0) treated with CS alone. At treatment failure or relapse, patients were randomized to receive 6 months of oral AZA or 6 pulses of CYC. Analyses were performed according to an intent-to-treat strategy. RESULTS: The mean +/- SD followup was 56.2 +/- 31.7 months. Among the 72 patients studied, 93% achieved remission with CS therapy alone, and 35% relapsed, mainly during the first year of treatment. Among the 19 patients randomized to additional immunosuppression because of treatment failure or relapse, 5 of 10 receiving AZA and 7 of 9 receiving pulse CYC achieved remission, but the difference was not statistically significant. Survival rates in all patients at 1 and 5 years were 100% and 97%, respectively. At the end of followup, 79% of the patients whose disease was in remission required low-dose CS therapy, mainly to control respiratory disease. CS-related adverse events were observed in 31% of the 72 patients. CONCLUSION: In CSS patients with an FFS of 0, survival was excellent, confirming the predictive value of the FFS in this disease. First-line therapy with CS achieved remission in most patients, but relapses were common, and one-third of them required additional immunosuppressive therapy. AZA or pulse CYC was fairly effective in treating CS-resistant disease or major relapses. Over the long term, most patients continued to take oral CS, which might explain the high rate of CS-related adverse events.

  • Administration, Oral
  • Adult
  • Aged
  • Azathioprine/*administration & dosage/adverse effects
  • Churg-Strauss Syndrome/*drug therapy/pathology
  • Cyclophosphamide/*administration & dosage/adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Immunosuppressive Agents/*administration & dosage/adverse effects
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Prospective Studies
  • Pulse Therapy, Drug
  • Recurrence
  • Remission Induction
  • Survival Rate
  • Treatment Outcome
Citation (ISO format)
RIBI, Camillo et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. In: Arthritis and rheumatism, 2008, vol. 58, n° 2, p. 586–594. doi: 10.1002/art.23198
Main files (1)
ISSN of the journal0004-3591

Technical informations

Creation03/27/2012 9:23:11 AM
First validation03/27/2012 9:23:11 AM
Update time03/14/2023 5:20:05 PM
Status update03/14/2023 5:20:04 PM
Last indexation02/12/2024 7:49:03 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack